No abstract available
MeSH terms
-
Acarbose / administration & dosage
-
Adrenergic alpha-1 Receptor Antagonists / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Ulcer Agents / adverse effects*
-
Antihypertensive Agents / administration & dosage
-
Aspirin / administration & dosage
-
Calcium Channel Blockers / administration & dosage
-
Cerebral Infarction / chemically induced*
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diffusion Magnetic Resonance Imaging
-
Drug-Related Side Effects and Adverse Reactions / complications*
-
Drug-Related Side Effects and Adverse Reactions / etiology
-
Eosinophilia / chemically induced*
-
Famotidine / adverse effects*
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy
-
Hypoglycemic Agents / administration & dosage
-
Labetalol / administration & dosage
-
Male
-
Metformin / administration & dosage
-
Middle Aged
-
Nifedipine / administration & dosage
-
Peptic Ulcer / complications
-
Peptic Ulcer / drug therapy*
-
Prazosin / administration & dosage
-
Prazosin / analogs & derivatives
-
Sulfonylurea Compounds / administration & dosage
Substances
-
Adrenergic alpha-1 Receptor Antagonists
-
Anti-Inflammatory Agents, Non-Steroidal
-
Anti-Ulcer Agents
-
Antihypertensive Agents
-
Calcium Channel Blockers
-
Hypoglycemic Agents
-
Sulfonylurea Compounds
-
Famotidine
-
glimepiride
-
Terazosin
-
Metformin
-
Nifedipine
-
Aspirin
-
Labetalol
-
Acarbose
-
Prazosin